Acute coronary syndrome diagnosis at hospital discharge: how often do we get it right in the emergency department?
Abstract
OBJECTIVE: Acute coronary syndrome (ACS) encompasses unstable angina (UA), non-ST elevation myocardial infarction (NSTEMI) and ST segment myocardial infarction (STEMI). In 2007-2008 in Australia, there were 95 000 hospitalisations for ACS. There is limited data about the level of agreement between the ED and hospital discharge diagnosis. The objective of the present study is to describe the proportion of ED patients with a concordant ACS hospital discharge diagnosis and determine factors associated with this.
METHODS: The present study was a retrospective case series of consecutive presentations of patients with ACS to the EDs of Southern Health, Victoria, Australia, during a 6 month period between August 2011 and January 2012.
RESULTS: One thousand and twenty-eight patients diagnosed with ACS in the ED were identified. Hospital discharge diagnosis was recorded for 704 cases. The mean age was 63 years (SD 14.5) and 69% were male. One hundred and nineteen patients (16.9%) were diagnosed with a STEMI, 322 (45.7%) with a NSTEMI and 263 (37.4%) with UA. There were 68.3% who had a concordant discharge diagnosis of ACS. An ED diagnosis of STEMI (87.4), English as the primary language (OR 1.81 [1.13-2.89]) and chest pain as the presenting complaint (OR 2.70 [1.72-4.23]) were associated with a concordant diagnosis of ACS.
CONCLUSION: Almost one-third of patients who are admitted to the hospital with ACS have a different hospital discharge diagnosis. English as a primary language and…
How strong is the evidence?
Evidence Hub reads this as a case series, done in people. Its evidence level is 5 of 5 (Very low · case / narrative / animal / in vitro / in silico). Case reports, narrative reviews, and animal, cell or computer-model studies give the weakest evidence for human health.
Read the paper
Related studies
- The Matrisome: In Silico Definition and In Vivo Characterization by Proteomics of Normal and Tumor Extracellular Matrices
- The Escherichia coli MG1655 in silico metabolic genotype: Its definition, characteristics, and capabilities
- In silico pharmacology for drug discovery: methods for virtual ligand screening and profiling
- In silico prediction of splice-altering single nucleotide variants in the human genome
- In silico clinical trials: how computer simulation will transform the biomedical industry
- In silico optimization of a guava antimicrobial peptide enables combinatorial exploration for peptide design
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.